Abstract Submission
Guidelines
The Conference Secretariat and Scientific Committee welcome you and invite you to submit abstracts in a broad range of categories.
​
Abstract submission deadline is June, 30th, 2025.
Abstract submission is to be made only through the abstract submission form.
​
The Scientific Committee will evaluate all abstract submissions anonymously and notifications of acceptance will be sent at the beginning of August 2025.
Outstanding abstracts will be selected for short (3 mins.) oral presentations.
​
Should you encounter any difficulties, please do not hesitate to contact the conference secretariat via email:
Shay@kldltd.com​​​​​​​
Suggested abstract categories:
🔹 AI, ML, AND CANCER 🔹 HEMATO-ONCOLOGY 🔹 CROSSING THE BBB AND BRAIN MALIGNANCIES🔹 IMMUNO-ONCOLOGY 🔹 LIFESTYLE AND CANCER 🔹 OTHER
Guidelines - Be sure to follow the instructions and check your document for spelling mistakes
​
-
Title – limited to 100 characters in UPPER CASE 🔹 Body – limited to 300 words
-
Information to be filled out in English only 🔹 Font - Times New Roman, Size 11
-
Margin 1 inch from al side & spacing 1.15 inch 🔹 One page only!
-
Authors - fill out all the author's details in the following format: First Name, Last Name, Affiliation
-
Abstracts can only be submitted by a student or scientist/clinician at Tel Aviv University and the affiliated medical centers. Names of the collaborator scientists cannot appear as first authors for studies conducted in collaboration with another research institute. ​
-
References may be inserted within the space allocated for the abstract but no figures, diagrams or frames are acceptable.​
-
Contents should be organized into the following sections: Objectives, Methods, Results, Conclusions & References (Optional), Please do not include figures.
Instructions for Abstract Submission
​
-
The Scientific Committee will review all the abstracts, and once complete, you will get information about presenting a poster or an oral presentation.
​
-
All abstracts must be submitted and presented in English appropriate for publication.
​
-
Upon submission, the Abstract Submitter confirms that the abstract has been reviewed and that all information is correct. The abstract will be published exactly as submitted.
​
-
The abstract submission constitutes acceptance of the authors regarding its publication (e.g. conference website, programs, other promotions, etc.).
​
-
The Abstract Submitter warrants and represents that he/she is the exclusive owner or has the rights of all the information and content (Hereafter: “Content”) provided to The 20th CBRC Biennial Meeting and Kaleidoscope LTD (Hereafter: “The Organizers”). The publication of the abstract does not infringe any third-party rights including, but not limited to, intellectual property rights.
​
-
Submitted abstracts containing clinical or pre-clinical data must be approved by the Helsinki Committee or by the local Institutional Review Board.
​
-
Abstracts can only be submitted by a student or scientist/clinician at Tel Aviv University and the affiliated medical centers as first authors. Names of the collaborator scientists may appear as additional authors in studies conducted in collaboration with another research institute.
​
-
The organizers have the right to remove any abstract which does not comply with the above.
​
-
Upon submission, the Abstract Submitter confirms that the contact details saved in the system are those of the corresponding author, who will be notified about the status of the abstract and will be responsible for informing the other authors about the status of the abstract.
​
-
For participants submitting abstracts, payment will only be processed following the scientific committee's selection of submitted abstracts for oral or poster presentation.​